ArticleMedical science monitor : international medical journal of experimental and clinical research2026
Combination of Astragaloside IV and Tetramethylpyrazine Promotes Angiogenesis via the MALAT1-CXCL12/CXCR4 Axis in Brain Endothelial Cells After Ischemic Injury.
Article in Medical science monitor : international medical journal of experimental and clinical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND Ischemic stroke causes severe neurological damage, and promoting angiogenesis in the ischemic penumbra is critical for neurovascular reconstruction and functional recovery. Astragaloside IV (AS-IV) and Tetramethylpyrazine (TMP) are a classic Chinese medicine combination for treating ischemic stroke, yet their synergistic mechanisms are unclear. This study aimed to investigate the enhanced effects of AS-IV combined with TMP on cerebral microvascular endothelial cells following ischemia-reperfusion injury and to explore the regulatory role of the lncRNA MALAT1-CXCL12/CXCR4 signaling axis. MATERIAL AND METHODS An oxygen-glucose deprivation/reperfusion (OGD/R) model was established using the bEnd.3 mouse brain microvascular endothelial cell line. Cells were treated with AS-IV, TMP, or their combination to evaluate therapeutic efficacy. Cell viability and migration capacity were assessed using CCK-8, wound healing, and Transwell assays. The expression levels of MALAT1 and angiogenesis-related markers (VEGFA, Ang1, Ang2, CXCL12, and CXCR4) were analyzed via qPCR, western blot, and immunofluorescence. To verify the mechanism, a stable MALAT1 knockdown model was constructed using lentiviral-mediated shRNA transduction. RESULTS OGD/R insult significantly reduced cell viability and migration, downregulated MALAT1 expression, and disrupted the Ang1/Ang2 balance. While AS-IV or TMP monotherapy partially mitigated these injuries, the combined treatment demonstrated a greater protective effect than either monotherapy. This enhancement was characterized by upregulation of MALAT1, activation of the CXCL12/CXCR4 pathway, and restoration of VEGFA and Ang1 protein expression. Furthermore, lentiviral-mediated MALAT1 silencing (shMALAT1) markedly impaired cell migration and angiogenic marker expression, effects that were partially rescued by the combined AS-IV and TMP intervention. CONCLUSIONS The combination of AS-IV and TMP exhibits an enhanced effect compared to either monotherapy in promoting endothelial migration and marker expression in vitro. These findings suggest that the protective mechanism is consistent with the involvement of the MALAT1-CXCL12/CXCR4 signaling axis. This study provides a preliminary cellular rationale for further in vivo validation of this combination therapy in rodent stroke models.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.